This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Motor neuropathy / SMN1-negative spinal muscular atrophy panel [38 genes]
Charcot-Marie-Tooth (CMT) disease, or sensorimotor neuropathy, is the most frequent hereditary neuromuscular disease, with a prevalence of 1/2,500 individuals (Suter and Sherer, 2003).
At the molecular level, CMT is a complex disorder, with at least 1,000 associated genetic variants in some 80 genes (Timmerman et al., 2014). In some wide described series, molecular alteration is identified in 60-70% of patients (80% of the demyelinating forms and 25% of the axonal forms) (Rossor et al., 2015). Approximately 90% of abnormalities are distributed in the PMP22, MPZ, GJB1, and MFN2 genes (DiVicenzo et al., 2015), although this value varies between populations, being particularly lower in regions with a high prevalence of recessive hereditary forms. Forty to fifty percent of CMT cases are demyelinating or type 1 (CMT1), of which 70-80% are caused by the duplication of a region of approximately 1,5 Mb which contains the PMP22 gene (CMT1A).
Hereditary motor neuropathy (HMN) comprises 10% of all hereditary neuropathies, with a diagnosis rate of 20-32% (Bansagi et al., 2017).
Request study
Informed consent
Steps to follow
Ask for information
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Motor neuropathy / SMN1-negative spinal muscular atrophy panel
Turnaround time (TAT): 6 weeks
Ref. S-202008639
Motor neuropathy / SMN1-negative spinal muscular atrophy panel: View panel
- AARS
- AGTPBP1
- ASAH1
- ATP7A
- BICD2
- BSCL2
- CHCHD10
- DCTN1
- DNAJB2
- DYNC1H1
- FBXO38
- GARS
- GSN
- HARS
- HEXB
- HINT1
- HSPB1
- HSPB3
- HSPB8
- IGHMBP2
- MFN2
- MORC2
- PLEKHG5
- REEP1
- SETX
- SIGMAR1
- SLC52A2
- SLC52A3
- SLC5A7
- SPTAN1
- SYT2
- TFG
- TRIP4
- TRPV4
- UBA1
- VAPB
- VRK1
- WARS
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.
Phenotypes
- ASAH1: Spinal muscular atrophy with progressive myoclonic epilepsy
- BICD2, DYNC1H1: Spinal muscular atrophy predominantly in lower limbs
- BSCL2: Silver syndrome
- CHCHD10: Spinal muscular atrophy, Jokela type
- HEXB: GM2 gangliosidosis
- SETX: Juvenile amyotrophic lateral sclerosis
- SLC52A2, SLC52A3: Brown-Vialetto-Van Laere / Fazio-Londe syndrome
- UBA1: X-linked spinal muscular atrophy
- VAPB: Spinal muscular atrophy, Finkel type
References
- Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, Greenslade M, Forester N, Duff J, Bradshaw A, Kleinle S, Boczonadi V, Steele H, Ramesh
- V, Franko E, Pyle A, Lochmüller H, Chinnery PF, Horvath R. Genetic heterogeneity of motor neuropathies. Neurology. 2017 Mar 28;88(13):1226-1234.
- DiVincenzo C, Elzinga CD, Medeiros AC, Karbassi I, Jones JR, Evans MC, Braastad CD, Bishop CM, Jaremko M, Wang Z, Liaquat K, Hoffman CA, York MD,
- Batish SD, Lupski JR, Higgins JJ. The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2014 Nov;2(6):522-9.
- Rossor AM, Evans MR, Reilly MM. A practical approach to the genetic neuropathies. Pract Neurol. 2015 Jun;15(3):187-98.
- Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci. 2003 Sep;4(9):714-26.
- Timmerman V, Strickland AV, Züchner S. Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes (Basel). 2014 Jan 22;5(1):13-32.